Cargando…

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

PURPOSE: This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians’ choice following the first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Hirmas, Nader, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, Loibl, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507224/ https://www.ncbi.nlm.nih.gov/pubmed/37690320 http://dx.doi.org/10.1016/j.breast.2023.08.007

Ejemplares similares

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Analysis of the oral microbiome during hormonal cycle and its alterations in menopausal women: the “AMICA” project
por: Tramice, A., et al.
Publicado: (2022)

Milena, l'amica di Kafka /
por: Buber-Neumann, Margarete 1901-1989
Publicado: (1986)

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
por: Schmidt, M., et al.
Publicado: (2022)

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores
por: Riecke, Kerstin, et al.
Publicado: (2021)

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
por: Laakmann, E., et al.
Publicado: (2022)

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
por: Laakmann, Elena, et al.
Publicado: (2020)

Agave amica a potential model for the study of agavins metabolism
por: Salomé-Abarca, Luis Francisco, et al.
Publicado: (2023)

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
por: Riecke, K., et al.
Publicado: (2023)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

amica: an interactive and user-friendly web-platform for the analysis of proteomics data
por: Didusch, Sebastian, et al.
Publicado: (2022)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer()
por: Loibl, Sibylle, et al.
Publicado: (2021)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

L'amica delle mogli ; Non si sa come ; Sogno (ma forse no) / Luigi Pirandello.
por: Pirandello, Luigi, 1867-1936

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
por: Parati, Maria Chiara, et al.
Publicado: (2022)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

Performance of the Emprint and Amica Microwave Ablation Systems in ex vivo Porcine Livers: Sphericity and Reproducibility Versus Size
por: Hendriks, P., et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
por: Hortobagyi, Gabriel N.
Publicado: (2018)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
por: James, Alexander D., et al.
Publicado: (2020)

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Explanatory Factors of Burnout in a Sample of Workers with Disabilities from the Special Employment Centres (SEC) of the Amica Association, Spain
por: Gutierrez-Martínez, Isabel, et al.
Publicado: (2021)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
por: Sharaf, Baha’, et al.
Publicado: (2023)

Tetramesa amica and its parasitoid Eurytoma amicophaga (Hymenoptera, Eurytomidae): two new species associated with medusahead, Taeniatherum caput-medusae (Poaceae)
por: Lotfalizadeh, Hossein, et al.
Publicado: (2020)

AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma
por: Feng, Ziyang, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hvo57js0dache7rq1khp67uatl